Tislelizumab before surgery and radiation for N3 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of immunotherapy (tislelizumab) followed by surgery and radiation for people with a specific type of advanced lung cancer (N3 stage NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has spread to lymph nodes in the chest (N3 stage).
- You are 18 or older.
- You have not had any prior cancer treatment for this lung cancer.
- You do not have certain gene changes like EGFR or ALK mutations.
- You are healthy enough for daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.